This New York Times article by Emily Anthes, published on November 28, 2023, explores the development of longevity drugs for dogs. The biotech company Loyal has made progress in this field, aiming to extend the healthy lifespan of dogs. The FDA has indicated openness to such drugs, with Loyal's product potentially reaching the market by 2026. The article also discusses other drugs in development, like rapamycin, and raises ethical considerations about extending pets' lives. It highlights the importance of quality of life in these extended years and the broader implications of such advancements.
For a full read, you can view the article on the New York Times website.